Bicycle Therapeutics Q2 2024 Update

TL;DR

Bicycle Therapeutics filed its Q2 10-Q, showing ongoing stock activity and financial updates.

AI Summary

Bicycle Therapeutics plc filed a 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities, including details on its common stock and at-market offerings. Specific financial figures and dates related to these activities are detailed within the filing.

Why It Matters

This filing provides insight into Bicycle Therapeutics' financial health and ongoing capital-raising activities, which are crucial for funding its drug development pipeline.

Risk Assessment

Risk Level: medium — Biotech companies like Bicycle Therapeutics are inherently risky due to the high failure rate in drug development and regulatory hurdles.

Key Numbers

• 2024-06-30 — Period End Date (Quarterly financial reporting period)
• 2024-01-01 — Period Start Date (Quarterly financial reporting period)

Key Players & Entities

• BICYCLE THERAPEUTICS PLC (company) — Filer
• 20240630 (date) — Period of Report
• 20240806 (date) — Filing Date
• BakerBrothersAdvisorsLpMember (company) — Affiliated Entity
• 2024-05-23 (date) — Purchase Agreement Date
• 2024-04-01 (date) — At-Market Offering Start Date

FAQ

Filing Documents

• bcyc-20240630x10q.htm (10-Q) — 2593KB
• bcyc-20240630xex3d1.htm (EX-3.1) — 876KB
• bcyc-20240630xex10d4.htm (EX-10.4) — 498KB
• bcyc-20240630xex31d1.htm (EX-31.1) — 14KB
• bcyc-20240630xex31d2.htm (EX-31.2) — 14KB
• bcyc-20240630xex32d1.htm (EX-32.1) — 10KB
• bcyc-20240630xex10d4001.jpg (GRAPHIC) — 1KB
• 0001558370-24-010949.txt ( ) — 11904KB
• bcyc-20240630.xsd (EX-101.SCH) — 90KB
• bcyc-20240630_cal.xml (EX-101.CAL) — 52KB
• bcyc-20240630_def.xml (EX-101.DEF) — 358KB
• bcyc-20240630_lab.xml (EX-101.LAB) — 623KB
• bcyc-20240630_pre.xml (EX-101.PRE) — 522KB
• bcyc-20240630x10q_htm.xml (XML) — 1650KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Shareholders' Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 36 Item 3. Quantitative and Qualitative Disclosure About Market Risk 51 Item 4.

Controls and Procedures

Controls and Procedures 52

- OTHER INFORMATION

PART II - OTHER INFORMATION 53 Item 1.

Legal Proceedings

Legal Proceedings 53 Item 1A .

Risk Factors

Risk Factors 53 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 110 Item 3. Defaults Upon Senior Securities 111 Item 4. Mine Safety Disclosures 111 Item 5. Other Information 111 Item 6. Exhibits 112

SIGNATURES

SIGNATURES i Table of Contents SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or this Quarterly Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements may be identified by such forward-looking terminology as "will," "may," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance our product candidates into, and successfully complete, clinical trials; our reliance on the success of our product candidates in our Bicycle Toxin Conjugate, or BTC molecules, Bicycle Tumor-Targeted Immune Cell Agonist , or Bicycle TICA molecules and other pipeline programs, including our Bicycle radionuclide conjugates, or BRC TM molecules; our ability to utilize our screening platform to identify and advance additional product candidates into clinical development; the timing or likelihood of regulatory filings and approvals; the commercialization of our product candidates, if approved;

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements . Bicycle Therapeutics plc Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 961,364 $ 526,423 Accounts receivable 233 — Prepaid expenses and other current assets 20,216 11,406 Research and development incentives receivable 46,443 24,039 Total current assets 1,028,256 561,868 Property and equipment, net 11,587 14,515 Operating lease right-of-use assets 10,933 13,169 Other assets 6,579 5,792 Total assets $ 1,057,355 $ 595,344 Liabilities and shareholders' equity Current liabilities: Accounts payable $ 7,453 $ 13,050 Accrued expenses and other current liabilities 28,135 31,509 Deferred revenue, current portion 11,619 24,978 Debt, current portion 22,404 — Total current liabilities 69,611 69,537 Debt, net of discount and current portion 8,505 30,698 Operating lease liabilities, net of current portion 6,730 9,382 Deferred revenue, net of current portion 93,994 110,216 Other longterm liabilities 4,702 4,579 Total liabilities 183,542 224,412 Commitments and contingencies (Note 11) Shareholders' equity: Ordinary shares, including non-voting ordinary shares, 0.01 nominal value; 154,385,145 and 59,612,613 shares authorized on June 30, 2024 and December 31, 2023, respectively; 68,941,242 and 42,431,766 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 889 550 Additional paid-in capital 1,452,151 883,446 Accumulated other comprehensive loss ( 1,092 ) ( 1,304 ) Accumulated deficit ( 578,135 ) ( 511,760 ) Total shareholders' equity 873,813 370,932 Total liabilities and shareholders' equity $ 1,057,355 $ 595,344 The accompanying notes are an integral part of the condensed consolidated financial statements 1 Table of Contents Bicycle Ther

View Full Filing

View this 10-Q filing on SEC EDGAR